<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-86951" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Cancer-Associated Thrombosis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Abu Zaanona</surname>
            <given-names>Mohammed I.</given-names>
          </name>
          <aff>Carle Foundation Hospital/ University of Illinois at Urbana Champaign</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mantha</surname>
            <given-names>Suparna</given-names>
          </name>
          <aff>Gandhi Medical College</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mohammed Abu Zaanona declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Suparna Mantha declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>17</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-86951.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Cancer-associated thrombosis is one of the leading causes of morbidity and mortality for cancer patients. It commonly occurs in patients with clinically active malignancy; however, there is a subset of patients where thrombosis can be the first manifestation of their cancer. This article outlines the etiology of this disease as well as describes the evaluation process and management of these patients. It also highlights the role of the interprofessional team in evaluating and treating patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describes the etiology of cancer-associated thrombosis</p></list-item><list-item><p>Summarize the diagnostic examination process for cancer-associated thrombosis</p></list-item><list-item><p>Reviews current guidelines for the treatment of cancer-associated thrombosis</p></list-item><list-item><p>Outlines the importance of collaboration and communication amongst the interprofessional team to improve outcomes for cancer patients with thromboembolic disease, especially if they are receiving anticoagulation.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=86951&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=86951">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-86951.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Patients with malignancy often experience increased risk of thrombosis, both venous and arterial. Clinical venous thromboembolism (VTE) remains one of the most common causes of mortality and morbidity among cancer patients. Pathophysiology of this disease stems from the hypercoagulable state related to the increasing production of substances like tissue factor that has high procoagulant activity. The thromboembolic disease can be the first manifestation of occult malignancy or more commonly occur within six months of a cancer diagnosis.&#x000a0;</p>
      </sec>
      <sec id="article-86951.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Multiple factors contribute to the increased risk of arterial and venous thromboembolism in cancer patients:</p>
        <list list-type="order">
          <list-item>
            <p>Tumor's tissue and anatomical factors&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Patient's comorbidities including obesity and advanced age</p>
          </list-item>
          <list-item>
            <p>Surgical and medical oncological treatment&#x000a0;</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-86951.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>The correlation between malignancy and thrombosis has been reported as early as 1823. Multiple published accounts show an increased risk of VTE in patients with malignancy with prevalence as high as 20%. A large case-control study in the Netherlands examined 3220 patients aged 18 to 70; the study found the overall risk of venous thrombosis to be 7-fold higher in patients with malignancy, the highest risk was in the first few months after diagnosis with the highest risk increase seen in patients with hematological malignancies, lung cancer, gastrointestinal cancer, or with distant metastases.<xref ref-type="bibr" rid="article-86951.r1">[1]</xref> In another case-control study in Minnesota, a 4-fold increase risk of VTE was found in patients with cancer, while patients receiving chemotherapy experienced an even higher risk.<xref ref-type="bibr" rid="article-86951.r2">[2]</xref> &#x000a0;</p>
        <p>Cancer patients also face an increased risk of arterial thromboembolism. In a large retrospective study with 279,719 pairs of cancer patients and matched controls, the 6-month incidence of myocardial infarction was 2.0% in cancer patients compared to 0.7% in control patients, while for ischemic stroke, the incidence was 3.0% for cancer patients compared to 1.6% for control patients. The study also found that cancer patients experiencing arterial thromboembolism had a poor prognosis, with a 3-fold increased hazard for death.<xref ref-type="bibr" rid="article-86951.r3">[3]</xref></p>
      </sec>
      <sec id="article-86951.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>The mechanisms of cancer-associated thrombosis are diverse. Tissue factor produced by malignant cells appears to trigger the coagulation cascade leading to the formation of Factor Xa, while some cancer cells can produce cancer procoagulant that acts directly on Factor Xa. In addition to the potential procoagulant effect of cancer cells, anti-cancer therapy has shown to be an additional cause of cancer-associated thrombosis. Different chemotherapeutic agents, including methotrexate, cyclophosphamide, cisplatin, doxorubicin, 5-fluorouracil, and lenalidomide, have been found to increase the risk of VTE and mortality significantly. Other causes include venous stasis due to compression of blood vessels by tumor or prolonged immobility in critically ill cancer patients.<xref ref-type="bibr" rid="article-86951.r4">[4]</xref><xref ref-type="bibr" rid="article-86951.r5">[5]</xref></p>
      </sec>
      <sec id="article-86951.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Taking a thorough history and performing a complete physical exam is essential. Thromboembolic events can either occur in patients with a known history of malignancy or can be the first manifestation. Patients can present with venous thromboembolism as deep venous thrombosis or pulmonary embolism and less likely as arterial thromboembolism with ischemic stroke and myocardial infarction.</p>
      </sec>
      <sec id="article-86951.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>In patients with unprovoked venous thromboembolism as well as patients with arterial thrombosis without identifiable cardiovascular risk factors should always raise suspicion for occult malignancy. Currently, there is insufficient evidence that extensive testing for occult malignancy in patients with unprovoked thrombotic disease would reduce cancer-related mortality.<xref ref-type="bibr" rid="article-86951.r6">[6]</xref> However, age-appropriate cancer screening is necessary.</p>
      </sec>
      <sec id="article-86951.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Given the increased risk of thromboembolism, patients with clinically active malignancy would benefit from thromboprophylaxis. A meta-analysis looking at a total of 33 trials and 11,972 patients provided more evidence that thromboprophylaxis decreased the incidence of VTE in cancer patients who were undergoing chemotherapy or surgery, while no apparent increase in the incidence of significant bleeding.<xref ref-type="bibr" rid="article-86951.r7">[7]</xref></p>
        <p>Current guidelines from the National Comprehensive Cancer Network (NCCN) recommend anticoagulation with unfractionated heparin or low molecular weight heparin in hospitalized cancer patients as thromboprophylaxis. Mechanical prophylaxis should be used instead of anticoagulation therapy in patients experiencing active bleeding, thrombocytopenia (platelet count below 50,000/mcL), evidence of hemorrhagic coagulopathy, or have an indwelling neuraxial catheter. Contraindications to the use of mechanical prophylaxis include acute deep venous thrombosis and severe arterial insufficiency.</p>
        <p>A recent meta-analysis addressed the question of the optimum duration of anticoagulation in cancer patients who are hospitalized with acute illnesses. This study looked at trials comparing standard-duration versus extended-duration anticoagulation prophylaxis. The risk of VTE was not significantly lower in the extended-duration prophylaxis group of patients but the risk of bleeding was about two-fold higher.<xref ref-type="bibr" rid="article-86951.r8">[8]</xref>&#x000a0;</p>
        <p>Regarding outpatient VTE prophylaxis, surgical pelvic or abdominal oncology patients would benefit from continuing VTE prophylaxis up to four weeks post-operation. The use of aspirin or anticoagulation therapy for patients with multiple myeloma on immunomodulatory medications is recommended based on risk stratification with the IMPEDE VTE score.<xref ref-type="bibr" rid="article-86951.r9">[9]</xref><xref ref-type="bibr" rid="article-86951.r10">[10]</xref>&#x000a0;For patients with solid cancers on chemotherapy and high Khorana score, prophylactic anticoagulation with direct oral anticoagulation or low molecular weight heparin showed a decrease in the incidence of pulmonary embolism.<xref ref-type="bibr" rid="article-86951.r11">[11]</xref></p>
        <p>Low molecular weight heparin (LMWH) remains the preferred anticoagulation option for the management of cancer-associated thrombosis.<xref ref-type="bibr" rid="article-86951.r12">[12]</xref>&#x000a0;The dosage recommendation for LMWH is 1 mg/kg every 12 hours, and 1 mg/kg once daily for patients with creatinine clearance less than 30 mL/minute. Avoid the use of LMWH in patients on dialysis. Other treatment options include direct oral anticoagulants like apixaban, rivaroxaban, edoxaban, fondaparinux, and warfarin. In the Caravaggio trial, researchers found apixaban to be non-inferior to LMWH in the treatment of cancer-associated VTE without an increased risk of significant bleeding.<xref ref-type="bibr" rid="article-86951.r13">[13]</xref></p>
        <p>Thrombolytic therapy can be used in patients with life or limb-threatening pulmonary embolism or acute deep vein thrombosis with consideration of the contraindications as intracranial tumors or metastasis, active bleeding, and history of intracranial hemorrhage. NCCN recommends a treatment duration minimum of 3 months or for the duration of active malignancy. For patients with non-catheter-related deep venous thrombosis or pulmonary embolism, indefinite anticoagulation is the recommendation.</p>
        <p>Continuing to assess for benefit vs. risks as well as monitoring for complications is essential. In patients with DVT located in inferior vena cava, iliac, femoral, and popliteal veins in addition to a contraindication to therapeutic anticoagulation, placement of retrievable vena cava filters can prevent pulmonary embolism. Once placed, it is important to periodically assess patients for resolution of contraindication, removal of the vena cava filters, and switching to therapeutic anticoagulation. For patients with catheter-associated thrombosis, treatment consists of removing the catheter or anticoagulation if the catheter remains.<xref ref-type="bibr" rid="article-86951.r10">[10]</xref>&#x000a0;</p>
        <p>In patients with superficial venous thrombosis, if it is related to peripheral catheter, current NCCN guidelines recommend removing the catheter and consider anticoagulation if thrombus progression occurs. In patients with superficial venous thrombosis non-catheter related especially in lower extremities, recommendations are for at least six weeks of anticoagulation.</p>
      </sec>
      <sec id="article-86951.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Malignancy is a cause of unprovoked thromboembolic disease. In a recently published retrospective study of 245 patients with venous thromboembolism, 4.1% had an occult malignancy.<xref ref-type="bibr" rid="article-86951.r14">[14]</xref>&#x000a0;However, during the evaluation of unprovoked thromboembolic disease, workup needs to include ruling out of thrombophilic disorders, nephrotic syndrome, antiphospholipid syndrome, myeloproliferative neoplasms, severe liver disease, and inflammatory bowel disease.</p>
      </sec>
      <sec id="article-86951.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Cancer-associated thrombosis increases mortality in cancer patients. In a review of 8 million Medicare patients admitted for VTE, the probability of death within six months of admission for cancer patients was 94% compared to 29% with non-cancer patients.<xref ref-type="bibr" rid="article-86951.r15">[15]</xref></p>
        <p>The majority of deaths in patients with cancer-associated thrombosis were related to arterial thrombosis (myocardial infarction, ischemic stroke) rather than VTE. In a review of 4466 ambulatory patients, thromboembolic disease accounted for 9.2% of deaths. 5.6% were related to arterial thrombosis.<xref ref-type="bibr" rid="article-86951.r16">[16]</xref></p>
      </sec>
      <sec id="article-86951.s11" sec-type="Complications">
        <title>Complications</title>
        <p>In cancer patients, experiencing a thromboembolic event has serious complications, including increased risk of recurrent thrombosis, increased risk of bleeding during anticoagulation therapy, increased hospitalization rates, and increased mortality.&#x000a0;</p>
      </sec>
      <sec id="article-86951.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients with active malignancy are at risk of developing venous and arterial thromboembolism. It is important to educate patients on their increased risk of developing cancer-associated thrombosis and possible presenting symptoms, including unilateral leg swelling, palpitations, chest pain, dyspnea, and stroke.&#x000a0;</p>
        <p>For non-cancer patients with unprovoked venous thromboembolism, it is crucial to perform age-appropriate cancer screening to evaluate for hidden malignancy.&#x000a0;</p>
      </sec>
      <sec id="article-86951.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Cancer-associated thrombosis adds to the complexity of care for cancer patients. The utilization of multidisciplinary care is essential. Primary care physicians, as well as primary oncologist/hematologist, will initiate evaluation and the discussion with the patient regarding benefits vs. risks of anticoagulation therapy if it is needed. They are also responsible for educating patients about side effects and perform close monitoring for risks of bleeding. Pharmacists are necessary to ensure correct dose adjustments&#x02014;nursing staff, whether inpatient or ambulatory, play a significant role in education and medication administration.&#x000a0;</p>
      </sec>
      <sec id="article-86951.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=86951&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=86951">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/cancer/cancer-associated-thrombosis/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=86951">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/86951/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=86951">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-86951.s15">
        <title>References</title>
        <ref id="article-86951.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Blom</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Doggen</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Osanto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rosendaal</surname>
                <given-names>FR</given-names>
              </name>
            </person-group>
            <article-title>Malignancies, prothrombotic mutations, and the risk of venous thrombosis.</article-title>
            <source>JAMA</source>
            <year>2005</year>
            <month>Feb</month>
            <day>09</day>
            <volume>293</volume>
            <issue>6</issue>
            <fpage>715</fpage>
            <page-range>715-22</page-range>
            <pub-id pub-id-type="pmid">15701913</pub-id>
          </element-citation>
        </ref>
        <ref id="article-86951.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heit</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Silverstein</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Mohr</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Petterson</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>O'Fallon</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Melton</surname>
                <given-names>LJ</given-names>
              </name>
            </person-group>
            <article-title>Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study.</article-title>
            <source>Arch Intern Med</source>
            <year>2000</year>
            <month>Mar</month>
            <day>27</day>
            <volume>160</volume>
            <issue>6</issue>
            <fpage>809</fpage>
            <page-range>809-15</page-range>
            <pub-id pub-id-type="pmid">10737280</pub-id>
          </element-citation>
        </ref>
        <ref id="article-86951.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Navi</surname>
                <given-names>BB</given-names>
              </name>
              <name>
                <surname>Reiner</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Kamel</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Iadecola</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Okin</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Elkind</surname>
                <given-names>MSV</given-names>
              </name>
              <name>
                <surname>Panageas</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>DeAngelis</surname>
                <given-names>LM</given-names>
              </name>
            </person-group>
            <article-title>Risk of Arterial Thromboembolism in Patients&#x000a0;With&#x000a0;Cancer.</article-title>
            <source>J Am Coll Cardiol</source>
            <year>2017</year>
            <month>Aug</month>
            <day>22</day>
            <volume>70</volume>
            <issue>8</issue>
            <fpage>926</fpage>
            <page-range>926-938</page-range>
            <pub-id pub-id-type="pmid">28818202</pub-id>
          </element-citation>
        </ref>
        <ref id="article-86951.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mukai</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Oka</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Mechanism and management of cancer-associated thrombosis.</article-title>
            <source>J Cardiol</source>
            <year>2018</year>
            <month>Aug</month>
            <volume>72</volume>
            <issue>2</issue>
            <fpage>89</fpage>
            <page-range>89-93</page-range>
            <pub-id pub-id-type="pmid">29588087</pub-id>
          </element-citation>
        </ref>
        <ref id="article-86951.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mitrugno</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tormoen</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Kuhn</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>McCarty</surname>
                <given-names>OJ</given-names>
              </name>
            </person-group>
            <article-title>The prothrombotic activity of cancer cells in the circulation.</article-title>
            <source>Blood Rev</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>30</volume>
            <issue>1</issue>
            <fpage>11</fpage>
            <page-range>11-9</page-range>
            <pub-id pub-id-type="pmid">26219246</pub-id>
          </element-citation>
        </ref>
        <ref id="article-86951.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Robertson</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Yeoh</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Broderick</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Stansby</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Effect of testing for cancer on cancer- or venous thromboembolism (VTE)-related mortality and morbidity in people with unprovoked VTE.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2018</year>
            <month>Nov</month>
            <day>08</day>
            <volume>11</volume>
            <issue>11</issue>
            <fpage>CD010837</fpage>
            <pub-id pub-id-type="pmid">30407621</pub-id>
          </element-citation>
        </ref>
        <ref id="article-86951.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Liu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Guo</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Peng</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Ma</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of thromboprophylaxis in cancer patients: a systematic review and meta-analysis.</article-title>
            <source>Ther Adv Med Oncol</source>
            <year>2020</year>
            <volume>12</volume>
            <fpage>1758835920907540</fpage>
            <pub-id pub-id-type="pmid">32215058</pub-id>
          </element-citation>
        </ref>
        <ref id="article-86951.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Osataphan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Patell</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Chiasakul</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Khorana</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Zwicker</surname>
                <given-names>JI</given-names>
              </name>
            </person-group>
            <article-title>Extended thromboprophylaxis for medically ill patients with cancer: a systemic review and meta-analysis.</article-title>
            <source>Blood Adv</source>
            <year>2021</year>
            <month>Apr</month>
            <day>27</day>
            <volume>5</volume>
            <issue>8</issue>
            <fpage>2055</fpage>
            <page-range>2055-2062</page-range>
            <pub-id pub-id-type="pmid">33861298</pub-id>
          </element-citation>
        </ref>
        <ref id="article-86951.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sanfilippo</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Luo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>TF</given-names>
              </name>
              <name>
                <surname>Fiala</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Schoen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wildes</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Mikhael</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kuderer</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Calverley</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Keller</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Carson</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Gage</surname>
                <given-names>BF</given-names>
              </name>
            </person-group>
            <article-title>Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score.</article-title>
            <source>Am J Hematol</source>
            <year>2019</year>
            <month>Nov</month>
            <volume>94</volume>
            <issue>11</issue>
            <fpage>1176</fpage>
            <page-range>1176-1184</page-range>
            <pub-id pub-id-type="pmid">31379000</pub-id>
          </element-citation>
        </ref>
        <ref id="article-86951.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Streiff</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Holmstrom</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Angelini</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ashrani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bockenstedt</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Chesney</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Fanikos</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Fenninger</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Fogerty</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Goldhaber</surname>
                <given-names>SZ</given-names>
              </name>
              <name>
                <surname>Gundabolu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hendrie</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>AI</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Mann</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>McMahon</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Millenson</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Morton</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ortel</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Ozair</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Paschal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Shattil</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Siddiqi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Smock</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Soff</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>TF</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Zakarija</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hammond</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Dwyer</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Engh</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>NCCN Guidelines Insights: Cancer-Associated Venous Thromboembolic Disease, Version 2.2018.</article-title>
            <source>J Natl Compr Canc Netw</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>16</volume>
            <issue>11</issue>
            <fpage>1289</fpage>
            <page-range>1289-1303</page-range>
            <pub-id pub-id-type="pmid">30442731</pub-id>
          </element-citation>
        </ref>
        <ref id="article-86951.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Yan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Tian</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>The effectiveness and safety of thromboprophylaxis in cancer patients based on Khorana score: a meta-analysis and systematic review of randomized controlled trials.</article-title>
            <source>Clin Transl Oncol</source>
            <year>2020</year>
            <month>Nov</month>
            <volume>22</volume>
            <issue>11</issue>
            <fpage>1992</fpage>
            <page-range>1992-2001</page-range>
            <pub-id pub-id-type="pmid">32246324</pub-id>
          </element-citation>
        </ref>
        <ref id="article-86951.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wang</surname>
                <given-names>TF</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Garcia</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Managing thrombosis in cancer patients.</article-title>
            <source>Res Pract Thromb Haemost</source>
            <year>2018</year>
            <month>Jul</month>
            <volume>2</volume>
            <issue>3</issue>
            <fpage>429</fpage>
            <page-range>429-438</page-range>
            <pub-id pub-id-type="pmid">30046747</pub-id>
          </element-citation>
        </ref>
        <ref id="article-86951.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Agnelli</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Becattini</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Meyer</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mu&#x000f1;oz</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Huisman</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Connors</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bauersachs</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Brenner</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Torbicki</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sueiro</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Lambert</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gussoni</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Campanini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fontanella</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vescovo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Verso</surname>
                <given-names>M</given-names>
              </name>
              <collab>Caravaggio Investigators</collab>
            </person-group>
            <article-title>Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer.</article-title>
            <source>N Engl J Med</source>
            <year>2020</year>
            <month>Apr</month>
            <day>23</day>
            <volume>382</volume>
            <issue>17</issue>
            <fpage>1599</fpage>
            <page-range>1599-1607</page-range>
            <pub-id pub-id-type="pmid">32223112</pub-id>
          </element-citation>
        </ref>
        <ref id="article-86951.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ferreira</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Pereira</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lynce</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nunes Marques</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Martins</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Cancer Screening in Patients with Unprovoked Thromboembolism: How to do it and Who Benefits?</article-title>
            <source>Cureus</source>
            <year>2020</year>
            <month>Feb</month>
            <day>10</day>
            <volume>12</volume>
            <issue>2</issue>
            <fpage>e6934</fpage>
            <pub-id pub-id-type="pmid">32051805</pub-id>
          </element-citation>
        </ref>
        <ref id="article-86951.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Levitan</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Dowlati</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Remick</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Tahsildar</surname>
                <given-names>HI</given-names>
              </name>
              <name>
                <surname>Sivinski</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Beyth</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rimm</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>1999</year>
            <month>Sep</month>
            <volume>78</volume>
            <issue>5</issue>
            <fpage>285</fpage>
            <page-range>285-91</page-range>
            <pub-id pub-id-type="pmid">10499070</pub-id>
          </element-citation>
        </ref>
        <ref id="article-86951.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khorana</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Francis</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Culakova</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Kuderer</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Lyman</surname>
                <given-names>GH</given-names>
              </name>
            </person-group>
            <article-title>Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy.</article-title>
            <source>J Thromb Haemost</source>
            <year>2007</year>
            <month>Mar</month>
            <volume>5</volume>
            <issue>3</issue>
            <fpage>632</fpage>
            <page-range>632-4</page-range>
            <pub-id pub-id-type="pmid">17319909</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
